RVMD vs VSTM
RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital. VSTM: A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated ovarian cancer and a pipeline focused on direct KRAS G12D inhibition.
Side-by-side fundamentals
| Metric | RVMD | VSTM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $183.03 | $5.89 | |
| Market cap as of 2026-07-23 | $39.0B | $527M | |
| PEG as of 2026-07-23 | -0.34 | n/a | |
| Net margin as of 2026-07-23 | -2833.9% | -391.2% | VSTM higher |
| Gross margin as of 2026-07-23 | n/a | +85.1% | |
| Operating margin as of 2026-07-23 | -3145.0% | -344.6% | VSTM higher |
| ROE as of 2026-07-23 | -54.1% | -163.6% | RVMD higher |
| ROA as of 2026-07-23 | -39.1% | -91.6% | RVMD higher |
| Debt / equity as of 2026-07-23 | 0.19 | 1.01 | RVMD lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +209.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +97.0% | |
| Beta as of 2026-07-23 | 1.41 | 0.38 | |
| 1-year return as of 2026-07-22 close | +378.3% | +11.8% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.